Johnson & Johnson to acquire Intra-Cellular Therapies in $14.6bn deal

TAGS

Johnson & Johnson has announced its largest biotech acquisition in over a year, agreeing to purchase for $14.6 billion. The deal highlights the pharmaceutical giant’s commitment to advancing treatments for neuropsychiatric and neurodegenerative disorders, two growing areas of need in global healthcare.

The acquisition will bring Intra-Cellular Therapies’ groundbreaking therapies, including the widely recognized CAPLYTA (lumateperone), into Johnson & Johnson’s expansive portfolio. CAPLYTA, a daily oral therapy, is approved for schizophrenia and depressive episodes associated with bipolar I and II disorders.

The transaction marks a pivotal step for Johnson & Johnson as it aims to address the increasing prevalence of mental health conditions with innovative solutions.

CAPLYTA: A Transformative Addition to Johnson & Johnson’s Portfolio

At the heart of this acquisition is CAPLYTA, a first-in-class treatment already making significant strides in mental health care. Its approval as both monotherapy and adjunctive therapy for bipolar underscores its versatility and potential to reshape treatment standards.

Experts anticipate that CAPLYTA will generate over $5 billion in peak annual sales. Recent Phase 3 trials have demonstrated its effectiveness in improving depressive symptoms when used alongside antidepressants. With a supplemental new drug application (sNDA) currently under review by the U.S. Food and Drug Administration (), CAPLYTA may soon gain approval as an adjunctive therapy for major depressive disorder (MDD).

See also  Glenmark Pharmaceuticals gets FDA final approval for Buphenyl generic

The therapeutic landscape for MDD has remained stagnant for over 15 years, making CAPLYTA a beacon of hope for millions of patients. If approved, it could set a new standard in treating depressive symptoms linked to bipolar and major depressive disorders.

Expanding Mental Health Therapies Amid a Global Crisis

Mental health conditions are among the leading causes of disability worldwide, with over one billion people affected globally. In the United States alone, approximately:

2.4 million adults live with schizophrenia.

6.1 million adults experience bipolar disorder.

21 million adults are diagnosed with MDD annually.

The acquisition reflects Johnson & Johnson’s strategic response to these growing challenges. By integrating Intra-Cellular Therapies’ proven treatments and promising pipeline, the company positions itself to address some of the most debilitating mental health conditions more effectively.

Promising Pipeline Strengthens Future Prospects

In addition to CAPLYTA, the acquisition includes ITI-1284, a Phase 2 compound with significant potential in treating generalized anxiety disorder (GAD) and Alzheimer’s disease-related psychosis. The drug targets two critical and underserved areas in mental health and neurodegeneration, further broadening Johnson & Johnson’s therapeutic reach.

The clinical-stage pipeline also includes studies on CAPLYTA for bipolar mania and relapse prevention in schizophrenia. Positive data from these trials highlight the drug’s potential to redefine care for conditions that currently lack effective long-term solutions.

See also  Digital medicine firm Akili Interactive to merge with Social Capital Suvretta

John Reed, Johnson & Johnson’s Executive Vice President of R&D, noted that the addition of CAPLYTA and its pipeline strengthens the company’s ability to meet the needs of patients with mental health challenges.

Strategic and Financial Implications

Under the terms of the agreement, Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies for $132 per share in cash. The transaction will be financed through a mix of cash and debt, preserving the company’s strong balance sheet and investment capacity.

The deal, expected to close later this year, is subject to shareholder and regulatory approvals. Following completion, Intra-Cellular Therapies’ stock will be delisted from the Nasdaq Global Select Market.

Analysts see this acquisition as a strategic move that aligns with Johnson & Johnson’s broader vision of advancing neuroscience. It also serves as a catalyst for near- and long-term growth in its pharmaceutical division.

Expert Perspectives on Mental Health Therapies

Jennifer Taubert, Worldwide Chairman of Innovative Medicine at Johnson & Johnson, expressed optimism about the collaboration, stating that it would allow the company to impact more patients living with neuropsychiatric and neurodegenerative disorders.

See also  Amgen submits BLA for Infliximab biosimilar ABP 710 to FDA

Dr. Sharon Mates, CEO of Intra-Cellular Therapies, echoed this sentiment, emphasizing her team’s pride in CAPLYTA’s success and its potential to help millions more patients under Johnson & Johnson’s stewardship.

With the mental health crisis showing no signs of abating, the acquisition underscores the urgent need for innovative solutions in this space. Johnson & Johnson’s focus on evidence-based therapies positions it as a leader in addressing these challenges.

Meeting the Growing Mental Health Demand

As mental health conditions rise globally, pharmaceutical companies are intensifying their efforts to develop novel treatments. Johnson & Johnson’s acquisition of Intra-Cellular Therapies exemplifies this trend, highlighting the importance of targeted therapies like CAPLYTA.

By integrating this innovative treatment into its portfolio, Johnson & Johnson aims to improve the quality of life for millions while driving growth in one of the pharmaceutical industry’s most dynamic sectors.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This